Indications
Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
Composition
- Active substance
- lanadelumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Takhzyro
- Active substance
- lanadelumab
- ATC code
- B06AC05
- Therapeutic area
- Angioedemas, Hereditary
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland Branch
- Status
- Authorised
- EU authorisation
- 22 Nov 2018